Text Size

Efficacy and Safety of ACH24 in the Treatment of Vitiligo

This study is not yet open for participant recruitment.
Verified August 2011 by Ache Laboratorios Farmaceuticos S.A.
Sponsor:
Information provided by (Responsible Party):
Ache Laboratorios Farmaceuticos S.A.
ClinicalTrials.gov Identifier:
NCT01419964
First received: August 17, 2011
Last updated: August 18, 2011
Last verified: August 2011
History of Changes
  Purpose

This is a multicenter clinical trial, phase III, randomized, placebo-controlled, parallel group, enroll 94 patients, to assess the efficacy of ACH24 in the repigmentation of achromatic areas in patients with vitiligo.


Condition Intervention Phase
Vitiligo
 Drug: Group 01
Drug: Group 02
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo

Resource links provided by NLM:

MedlinePlus related topics: Vitiligo
U.S. FDA Resources

Further study details as provided by Ache Laboratorios Farmaceuticos S.A.:

Primary Outcome Measures:
  • Repigmentation of the affected area assessed by VASI (vitiligo area scoring index). [ Time Frame: Baseline compared to the end of 18 months of treatment ] [ Designated as safety issue: No ]
    It is considered successful treatment a repigmentation of greater than or equal to 50% of the affected area assessed by VASI (vitiligo area scoring index).


Secondary Outcome Measures:
  • Quality of life questionnaire [ Time Frame: Baseline and each 12 weeks of treatment (V0, V3, V6, V9, V12, V15, V18) ] [ Designated as safety issue: No ]
    Dermatology Life Quality Index (DLQI)

  • Safety descriptive about occurence of adverse events, evaluation of results of general physical examination. [ Time Frame: Will be evaluated during whole study, at the baseline and after 18 months of treatment ] [ Designated as safety issue: Yes ]
    Collection of safety data throughout the whole study period


Estimated Enrollment: 94
Study Start Date: January 2012
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 01
ACH24 - Standardized extract of Stachytarpheta cayensensis Vahl (Verbenaceae)
 Drug: Group 01
ACH24 - Standardized extract of Stachytarpheta cayensensis Vahl (Verbenaceae)
Placebo Comparator: Group 02
Placebo
 Drug: Group 02
Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients of both sexes, aged between 18 and 65 years, remaining the feasibility of a legal guardian in accordance with need, able to understand and provide written informed consent and able to allow compliance at the treatment and the requirements of the protocol;
  • Presence of generalized vitiligo;
  • Able to comprehend and willing to provide written informed consent in accordance with institutional and regulatory guidelines.

Exclusion Criteria:

  • Patients with:

    • Inflammatory diseases;
    • Alopecia Areata;
    • Diabetes Type I;
    • Asthma;
    • Collagen disease;
    • Atopic dermatitis;
    • Psoriasis;
    • Autoimmune thyroid disease (self reported). ¬ Thyroid problems (represents 15% of people with vitiligo), exclude only those who need to do treatment with corticosteroid or immunosuppressive.
  • Women of childbearing age who had tested positive for pregnancy, or who do not use acceptable contraceptive method, or do not agree to practice reliable contraception during the study;
  • Woman in pregnancy or lactation period;
  • Known allergic reaction against the phytomedicine as assessed by medical history;
  • Patient that is taking any prohibited medication (Item 9.3);
  • Participation in last one year of clinical protocols, unless it can be direct benefit to subject;
  • Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the subject or interfere with the endpoints of study.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Ache Laboratorios Farmaceuticos S.A.
ClinicalTrials.gov Identifier: NCT01419964     History of Changes
Other Study ID Numbers: ACH-VTL-03(09/11)
Study First Received: August 17, 2011
Last Updated: August 18, 2011
Health Authority: Brazil: Ethics Committee
Brazil: Ministry of Health

Keywords provided by Ache Laboratorios Farmaceuticos S.A.:
Vitiligo
Macular depigmentation
Stachytarpheta cayensensis

Additional relevant MeSH terms:
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases

ClinicalTrials.gov processed this record on May 19, 2013